You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
SBC: MICROBIOTIX, INC. Topic: NIAIDAbstract Segmented negative-sense, single-stranded RNA viruses (sNSVs), which include bunyaviruses, are causative agents of human diseases. Rift Valley Fever Virus (RVFV), a bunyavirus, causes hemorrhagic fever in humans with a case fatality rate of patients developing hemorrhagic fever reaching approximately 50% and has been classified by the NIAID as a Category A Priority Pathogen. RVFV is mosqu ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of Broad-Spectrum CyclicAmphiphilic Peptides against Multidrug-Resistant Bacteria
SBC: AJK BIOPHARMACEUTICAL LLC Topic: NIAIDABSTRACT The emergence of antibacterial resistance to common frontline antibiotics, such as methicillin, vancomycin, cephalosporins, and carbapenem, have created a global public health challenge for millions of patients. It is therefore critical to discover and commercialize new antimicrobial agents that can successfully neutralize multidrug-resistant bacteria (MDRB) with minimal toxicity. The obj ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Computer-based Learning to Enhance ADRD Care in Prison: Just Care for Dementia
SBC: KLEIN BUENDEL, INC Topic: RProject Summary/Abstract U.S. prison systems face sharply increased demands in caring for older people living in prisons. Alzheimerandapos;s Disease and related dementias (ADRD) are age-related diseases. Prison populations are over- represented by minority populations who experience disparities in prevalence and incidence of dementia. Prison health, social, and security staff perceive they lack th ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development and characterization of HIV-1 Tat degraders
SBC: Thimble Therapeutics Inc Topic: NIAIDAbstractDespite effective antiretroviral therapy (ART), latent proviruses can reinitiate viral production upon cell stimulation or treatment interruption. The viral Tat protein enhances transcript elongation from the HIV-1 promoter, controlling the switch between latency and active viral production. The block-and-lock functional cure aims at the transcriptional silencing of the viral reservoir, re ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Next generation anti-cancer drugdelivering cement for bone metastasis patients
SBC: CURER INC Topic: 102Abstract Our mission is to develop an innovative anti-cancer drug delivering bone cement for bone metastasis patients, which can be injected into metastasis-caused bone degeneration sites in a minimally invasive manner, to regress cancer, regenerate bone, and stop the pain. Metastasis is the main cause of cancer death. Bone is one of the most frequent cancer metastatic sites. About 350,000 America ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A web-based platform to support team-based genome diagnostics
SBC: Frameshift Labs, Inc. Topic: 172Summary/Abstract Genomic sequencing is rapidly becoming a standard tool in diagnosing complex diagnostic cases, especially in critically ill newborns, and patients suffering from rare diseases. Current programs focused on addressing these cases utilise a team-based approach to identify, interpret and evaluate a patient’s genetic variants. These diverse teams include bioinformaticians, medical ge ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
The First Non-Surgical Anti-Stomal Prolapse Medical Device to Treat and Prevent Stomal Prolapse
SBC: PEDIATRIC MEDICAL DEVICE COMPANY, LLC Topic: 300ABSTRACT Intestinal stomas such as ileostomies and colostomies are openings of the intestinal tract surgically exteriorized onto the abdominal surface to divert enteric content away from distal cancer, obstruction, inflammation, and infection 5. In the US alone, about 1.5 million people have stomas14. Prolapse, or protrusion, of the bowel through the stoma is a common complication that can cause p ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
System for documenting and tracking skin lesions
SBC: Lumo Imaging LLC Topic: NIBIBProject Summary The objective of this STTR proposal is to develop a system for longitudinally tracking the locations and morphologic changes to all Pigmented Skin Lesions on the patient’s body. The proposed software will build on a previously developed Total Body Photography (TBP) system, called Lumo Scanner, that can provide unprecedented resolution across the entire body surface. Skin cancers, ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Translating an In-Person Brief, Bystander Bullying Intervention (STAC) to a Technology-Based- Phase II
SBC: KLEIN BUENDEL, INC Topic: 102While studies support the efficacy of comprehensive, school-wide interventions in reducing bullying, these types of programs can require significant time and financial resources for implementation, resulting in barriers to providing school-based bullying prevention, especially in low-income and rural communities. Additionally, although training bystanders to act as “defenders” on behalf of tar ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Leveraging platelet signal transduction for personalized antiplatelet therapy
SBC: PlateletDiagnostics, LLC Topic: NHLBIProject Summary/Abstract Platelet-mediated thrombosis causes both coronary arterial disease (CAD) and stroke, the first and fifth most common causes of mortality in the US. Antiplatelet agents, typically aspirin and/or clopidogrel, significantly improve survival in patients with CAD or stroke and have remained a mainstay of treatment for more than two decades. Yet despite the consensus that platel ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health